nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—Epinephrine—TNF—acquired immunodeficiency syndrome	0.0288	1	CrCbGaD
Dipivefrin—BCHE—blood plasma—acquired immunodeficiency syndrome	0.0211	0.074	CbGeAlD
Dipivefrin—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.018	0.0633	CbGeAlD
Dipivefrin—Conjunctivitis—Nevirapine—acquired immunodeficiency syndrome	0.0176	0.0534	CcSEcCtD
Dipivefrin—Conjunctivitis—Stavudine—acquired immunodeficiency syndrome	0.017	0.0516	CcSEcCtD
Dipivefrin—Conjunctivitis—Abacavir—acquired immunodeficiency syndrome	0.0167	0.0508	CcSEcCtD
Dipivefrin—ACHE—spinal cord—acquired immunodeficiency syndrome	0.0151	0.0531	CbGeAlD
Dipivefrin—Conjunctivitis—Delavirdine—acquired immunodeficiency syndrome	0.0124	0.0377	CcSEcCtD
Dipivefrin—Conjunctivitis—Ritonavir—acquired immunodeficiency syndrome	0.0115	0.0349	CcSEcCtD
Dipivefrin—Conjunctivitis—Saquinavir—acquired immunodeficiency syndrome	0.011	0.0335	CcSEcCtD
Dipivefrin—Pain—Didanosine—acquired immunodeficiency syndrome	0.011	0.0333	CcSEcCtD
Dipivefrin—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.0107	0.0325	CcSEcCtD
Dipivefrin—BCHE—skin of body—acquired immunodeficiency syndrome	0.0101	0.0356	CbGeAlD
Dipivefrin—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00986	0.03	CcSEcCtD
Dipivefrin—ACHE—brain—acquired immunodeficiency syndrome	0.00975	0.0342	CbGeAlD
Dipivefrin—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00955	0.029	CcSEcCtD
Dipivefrin—Pain—Stavudine—acquired immunodeficiency syndrome	0.00952	0.0289	CcSEcCtD
Dipivefrin—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00944	0.0287	CcSEcCtD
Dipivefrin—ACHE—lymph node—acquired immunodeficiency syndrome	0.00943	0.0331	CbGeAlD
Dipivefrin—Pain—Abacavir—acquired immunodeficiency syndrome	0.00937	0.0285	CcSEcCtD
Dipivefrin—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00924	0.0324	CbGeAlD
Dipivefrin—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.00899	0.0273	CcSEcCtD
Dipivefrin—ADRA1A—blood—acquired immunodeficiency syndrome	0.00869	0.0305	CbGeAlD
Dipivefrin—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.0086	0.0262	CcSEcCtD
Dipivefrin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00849	0.0258	CcSEcCtD
Dipivefrin—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00829	0.0252	CcSEcCtD
Dipivefrin—ADRA2C—blood—acquired immunodeficiency syndrome	0.00828	0.029	CbGeAlD
Dipivefrin—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00827	0.0252	CcSEcCtD
Dipivefrin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00822	0.025	CcSEcCtD
Dipivefrin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.0082	0.0249	CcSEcCtD
Dipivefrin—BCHE—digestive system—acquired immunodeficiency syndrome	0.00811	0.0284	CbGeAlD
Dipivefrin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00808	0.0246	CcSEcCtD
Dipivefrin—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.00798	0.028	CbGeAlD
Dipivefrin—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00796	0.0242	CcSEcCtD
Dipivefrin—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00794	0.0241	CcSEcCtD
Dipivefrin—BCHE—blood—acquired immunodeficiency syndrome	0.00773	0.0271	CbGeAlD
Dipivefrin—Pain—Indinavir—acquired immunodeficiency syndrome	0.00769	0.0234	CcSEcCtD
Dipivefrin—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00768	0.0269	CbGeAlD
Dipivefrin—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00766	0.0233	CcSEcCtD
Dipivefrin—BCHE—bone marrow—acquired immunodeficiency syndrome	0.00748	0.0262	CbGeAlD
Dipivefrin—BCHE—spinal cord—acquired immunodeficiency syndrome	0.00744	0.0261	CbGeAlD
Dipivefrin—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00734	0.0223	CcSEcCtD
Dipivefrin—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00727	0.0221	CcSEcCtD
Dipivefrin—ADRA2C—lung—acquired immunodeficiency syndrome	0.00726	0.0255	CbGeAlD
Dipivefrin—BCHE—vagina—acquired immunodeficiency syndrome	0.00716	0.0251	CbGeAlD
Dipivefrin—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.00706	0.0247	CbGeAlD
Dipivefrin—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00695	0.0211	CcSEcCtD
Dipivefrin—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.00679	0.0238	CbGeAlD
Dipivefrin—BCHE—lung—acquired immunodeficiency syndrome	0.00677	0.0238	CbGeAlD
Dipivefrin—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.00672	0.0236	CbGeAlD
Dipivefrin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00663	0.0202	CcSEcCtD
Dipivefrin—ADRA2A—blood—acquired immunodeficiency syndrome	0.00661	0.0232	CbGeAlD
Dipivefrin—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.00647	0.0227	CbGeAlD
Dipivefrin—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00643	0.0196	CcSEcCtD
Dipivefrin—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00637	0.0223	CbGeAlD
Dipivefrin—BCHE—nervous system—acquired immunodeficiency syndrome	0.00627	0.022	CbGeAlD
Dipivefrin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00626	0.019	CcSEcCtD
Dipivefrin—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00619	0.0188	CcSEcCtD
Dipivefrin—ADRA2A—vagina—acquired immunodeficiency syndrome	0.00613	0.0215	CbGeAlD
Dipivefrin—BCHE—central nervous system—acquired immunodeficiency syndrome	0.00604	0.0212	CbGeAlD
Dipivefrin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00599	0.0182	CcSEcCtD
Dipivefrin—Pain—Lamivudine—acquired immunodeficiency syndrome	0.0059	0.018	CcSEcCtD
Dipivefrin—ADRA2A—lung—acquired immunodeficiency syndrome	0.00579	0.0203	CbGeAlD
Dipivefrin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00554	0.0168	CcSEcCtD
Dipivefrin—ADRA1A—brain—acquired immunodeficiency syndrome	0.00539	0.0189	CbGeAlD
Dipivefrin—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.00536	0.0188	CbGeAlD
Dipivefrin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00533	0.0162	CcSEcCtD
Dipivefrin—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.00517	0.0181	CbGeAlD
Dipivefrin—ADRA2C—brain—acquired immunodeficiency syndrome	0.00514	0.018	CbGeAlD
Dipivefrin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00509	0.0155	CcSEcCtD
Dipivefrin—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.00497	0.0174	CbGeAlD
Dipivefrin—BCHE—brain—acquired immunodeficiency syndrome	0.00479	0.0168	CbGeAlD
Dipivefrin—BCHE—lymph node—acquired immunodeficiency syndrome	0.00463	0.0162	CbGeAlD
Dipivefrin—ADRA2A—brain—acquired immunodeficiency syndrome	0.0041	0.0144	CbGeAlD
Dipivefrin—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00396	0.0139	CbGeAlD
Dipivefrin—ACHE—Metabolism—TAT—acquired immunodeficiency syndrome	0.00136	0.00379	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00135	0.00379	CbGpPWpGaD
Dipivefrin—ADRA2C—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.00134	0.00377	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.0013	0.00365	CbGpPWpGaD
Dipivefrin—ADRA2C—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.0013	0.00364	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.0013	0.00363	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00129	0.00361	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00129	0.0036	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00126	0.00354	CbGpPWpGaD
Dipivefrin—ADRA2B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00125	0.00351	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00122	0.00341	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—TAT—acquired immunodeficiency syndrome	0.00121	0.00339	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00119	0.00332	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00119	0.00332	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00118	0.0033	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00117	0.00329	CbGpPWpGaD
Dipivefrin—ADRA2C—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00117	0.00328	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00116	0.00326	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00116	0.00326	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00115	0.00323	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00115	0.00322	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00111	0.0031	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00111	0.0031	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00111	0.0031	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0011	0.00309	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0011	0.00309	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.0011	0.00308	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00109	0.00306	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00109	0.00306	CbGpPWpGaD
Dipivefrin—ADRA2A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.00109	0.00306	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00109	0.00306	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00109	0.00304	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00108	0.00303	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00107	0.00299	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00106	0.00298	CbGpPWpGaD
Dipivefrin—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00106	0.00296	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00105	0.00295	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	0.00105	0.00294	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00104	0.00292	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00103	0.0029	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00103	0.0029	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00103	0.00289	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00103	0.00288	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00101	0.00283	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000997	0.00279	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000988	0.00277	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000985	0.00276	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000984	0.00276	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000978	0.00274	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000966	0.0027	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000962	0.00269	CbGpPWpGaD
Dipivefrin—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000951	0.00266	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00095	0.00266	CbGpPWpGaD
Dipivefrin—ADRA2B—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000948	0.00266	CbGpPWpGaD
Dipivefrin—ADRA2B—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000938	0.00263	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000931	0.00261	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000914	0.00256	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000904	0.00253	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000904	0.00253	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000904	0.00253	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000894	0.0025	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000893	0.0025	CbGpPWpGaD
Dipivefrin—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000886	0.00248	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000884	0.00247	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000883	0.00247	CbGpPWpGaD
Dipivefrin—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000876	0.00245	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000861	0.00241	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	0.000853	0.00239	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000843	0.00236	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00084	0.00235	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00084	0.00235	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000839	0.00235	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000832	0.00233	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000821	0.0023	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000814	0.00228	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.0008	0.00224	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000799	0.00224	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000787	0.0022	CbGpPWpGaD
Dipivefrin—ADRA2B—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000761	0.00213	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000759	0.00213	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000756	0.00212	CbGpPWpGaD
Dipivefrin—ACHE—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000751	0.0021	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000749	0.0021	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000742	0.00208	CbGpPWpGaD
Dipivefrin—ADRA2B—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000742	0.00208	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000725	0.00203	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.00072	0.00201	CbGpPWpGaD
Dipivefrin—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000712	0.00199	CbGpPWpGaD
Dipivefrin—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000711	0.00199	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000709	0.00199	CbGpPWpGaD
Dipivefrin—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000693	0.00194	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000688	0.00193	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000668	0.00187	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000666	0.00186	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00066	0.00185	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000657	0.00184	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000639	0.00179	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000639	0.00179	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000639	0.00179	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000631	0.00177	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000631	0.00177	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000626	0.00175	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000626	0.00175	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000624	0.00175	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000622	0.00174	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00062	0.00174	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000618	0.00173	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000618	0.00173	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000605	0.00169	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000597	0.00167	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000597	0.00167	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000597	0.00167	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000585	0.00164	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000585	0.00164	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000578	0.00162	CbGpPWpGaD
Dipivefrin—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000577	0.00162	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000576	0.00161	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000571	0.0016	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000568	0.00159	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000568	0.00159	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000565	0.00158	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000563	0.00158	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000561	0.00157	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000561	0.00157	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000546	0.00153	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000544	0.00152	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00054	0.00151	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000531	0.00149	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000531	0.00149	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000531	0.00149	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000522	0.00146	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000522	0.00146	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000511	0.00143	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000511	0.00143	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000507	0.00142	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000505	0.00141	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000494	0.00138	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000485	0.00136	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000485	0.00136	CbGpPWpGaD
Dipivefrin—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000484	0.00135	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000476	0.00133	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000475	0.00133	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000475	0.00133	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000473	0.00133	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000472	0.00132	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00047	0.00132	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000469	0.00131	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000464	0.0013	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000464	0.0013	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000463	0.0013	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000459	0.00128	CbGpPWpGaD
Dipivefrin—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000452	0.00126	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000445	0.00125	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000439	0.00123	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000438	0.00123	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000432	0.00121	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000431	0.00121	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000431	0.00121	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000429	0.0012	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000427	0.0012	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000426	0.00119	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000423	0.00119	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00042	0.00118	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000404	0.00113	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000401	0.00112	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000398	0.00111	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000395	0.00111	CbGpPWpGaD
Dipivefrin—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000392	0.0011	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00039	0.00109	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00039	0.00109	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000389	0.00109	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000385	0.00108	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000383	0.00107	CbGpPWpGaD
Dipivefrin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000373	0.00105	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000369	0.00103	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000367	0.00103	CbGpPWpGaD
Dipivefrin—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000366	0.00103	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000364	0.00102	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000361	0.00101	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000357	0.001	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000356	0.000996	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000353	0.000989	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000353	0.000987	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00035	0.000981	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000348	0.000974	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000336	0.00094	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000336	0.00094	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000334	0.000934	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000331	0.000928	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000331	0.000928	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000328	0.000918	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000325	0.000911	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000323	0.000905	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000322	0.000903	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000318	0.000891	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000314	0.000878	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000314	0.000878	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.0003	0.000839	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000298	0.000833	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000296	0.000827	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000292	0.000816	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000274	0.000768	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000274	0.000768	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000271	0.000759	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000255	0.000715	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000255	0.000713	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000255	0.000713	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000252	0.000706	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000252	0.000704	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000248	0.000695	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000248	0.000694	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000245	0.000685	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000239	0.000668	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—ALB—acquired immunodeficiency syndrome	0.000236	0.000662	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000235	0.000658	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000232	0.000648	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.00023	0.000644	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000227	0.000636	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000225	0.00063	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000222	0.000622	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000215	0.000602	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—ALB—acquired immunodeficiency syndrome	0.000211	0.00059	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00021	0.000589	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000209	0.000584	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000205	0.000575	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000202	0.000567	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000194	0.000543	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000191	0.000534	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000188	0.000526	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000188	0.000526	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000184	0.000515	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	0.000183	0.000513	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000175	0.000489	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000171	0.000478	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	0.000149	0.000417	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000133	0.000372	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000132	0.00037	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000131	0.000367	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000131	0.000366	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000124	0.000348	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000124	0.000346	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000109	0.000304	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000108	0.000302	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000101	0.000282	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.0001	0.000281	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.82e-05	0.000219	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.72e-05	0.000216	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.3e-05	0.000204	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.38e-05	0.000179	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.93e-05	0.000166	CbGpPWpGaD
